Table 1 Demographic data and patient characteristics
Variable | Caspofungin monotherapy (N = 36) | Caspofungin combination therapy (N = 6) | Total (N = 42) |
|---|---|---|---|
Gender, n (%) | |||
Male | 22 (61%) | 2 (33%) | 24 (57%) |
Female | 14 (39%) | 4 (67%) | 18 (43%) |
Age (years; median (range)) | 59 (20 to 75) | 42 (17 to 57) | 57 (17 to 75) |
Affected organ, n | |||
Lung | 35 | 6 | 41 |
Trachea | 1 | 0 | 1 |
Neutropenic status at start of caspofungin therapy | |||
Neutrophilic granulocytes < 500/μL | 27 (75%) | 1 (17%) | 28 (67%) |
Neutrophilic granulocytes ≥ 500/μL | 9 (25%) | 5 (83%) | 14 (33%) |
No. of risk factors per patient (median (range)) | 5 (3 to 9) | 7 (3 to 7) | 5 (3 to 9) |
Risk factors, n (%)*' | |||
Active cancer | 35 (97%) | 4 (67%) | 39 (93%) |
Immunosuppressive therapy | 34 (94%) | 5 (83%) | 39 (93%) |
Neutropenia at hospitalization | 26 (72%) | 1 (17%) | 27 (64%) |
Allogeneic HSCT | 5 (14%) | 3 (50%) | 8 (19%) |
Prior colonization with fungi | 5 (14%) | 1 (17%) | 6 (14%) |
Acute renal disease | 4 (11%) | 1 (17%) | 5 (12%) |
Diabetes mellitus | 4 (11%) | 1 (17%) | 5 (12%) |
Autologous HSCT | 4 (11%) | 0 | 4 (10%) |
AIDS/HIV disease | 3 (8%) | 0 | 3 (7%) |